Peptide Radiation Therapy Before Immunotherapy Shrank Neuroendocrine Tumors More Than Either Treatment Alone

In 96 humanized mice with gastroenteropancreatic NETs, the early PRRT group (PRRT on day 0 followed by anti-PD1 on day 3) showed the most significant tumor reduction: 205 mm³ to 78 mm³ over 21 days (p=0.0074). PET/MRI imaging confirmed the strongest T-cell activation in this group, with SUVmax increasing from 0.73 to 3.36 (p<0.05) for granzyme-B uptake — indicating robust cytotoxic T-cell activation. The simultaneous and anti-PD1-first groups showed less tumor growth reduction, and PRRT or anti-PD1 alone were least effective.

Researchers implanted human QGP-1 neuroendocrine tumor cells into immunodeficient mice engrafted with human immune cells (96 mice total, 12 per group). Six groups received: pembrolizumab alone, [177Lu]DOTATATE PRRT alone, simultaneous treatment, delayed PRRT (anti-PD1 first), early PRRT (PRRT first then anti-PD1), or vehicle control. Granzyme-B-specific PET/MRI tracked T-cell activation before and 6 days after treatment. Response was measured by tumor growth over 21 days and histological analysis.

Neuroendocrine tumors have limited treatment options and often resist immunotherapy. This study reveals that PRRT can 'prime' the immune system — the radiation delivered by the peptide carrier triggers an inflammatory response that makes immunotherapy much more effective. The finding that sequence matters (PRRT first works best) provides a practical framework for designing combination clinical trials.

PRRT using [177Lu]DOTATATE is already FDA-approved for neuroendocrine tumors, and immunotherapy with pembrolizumab is widely used in oncology. This study provides preclinical evidence that combining these two approved treatment modalities — in the right sequence — could dramatically improve outcomes for NET patients. The concept of using radiation to prime the immune response is gaining traction across oncology and could extend to other tumor types.

This is a preclinical study using humanized mice, which do not fully replicate the human immune system or tumor microenvironment. The human immune reconstitution model has inherent limitations, including potential graft-versus-host effects. The 21-day follow-up is short and doesn't capture long-term outcomes or potential toxicity. The gastroenteropancreatic NET model may not represent all NET subtypes.